Full-Time

Senior Research Associate

Chemical Biology

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$95k - $120kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree or Master’s degree in molecular biology, biochemistry, biotechnology, or related field
  • 5+ years of experience in a cell biology/molecular biology role
  • Hands-on experience culturing, manipulating and characterizing mammalian cells: cell culture, viability and other bioassays (e.g. western blot, qPCR, CTG)
  • Experience with biochemical and recombinant protein assays and protein analysis by LC-MS
  • Excellent written and verbal communication, attention to detail, and record keeping
  • An energetic and proactive team player with the ability to work efficiently in a dynamic company environment
Responsibilities
  • Work with scientists in the Chemical Biology and Proteomics team to follow up on biochemical and cellular high-throughput screening hits and perform mechanistic experiments as part of hit validation efforts
  • Perform bioassays to interrogate effects of novel compounds on cellular pathways, including plate-based cellular assays using reagent kits and automated liquid handlers
  • Engineer cell lines and establish cellular assay systems
  • Maintain cultures of multiple cancer cell lines to support experimental efforts
  • Generate high quality data in a timely manner and maintain detailed experimental records
  • Work with project scientists to process and analyze data and design new experiments
  • Regularly and effectively communicate findings at group meetings

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to tailor their research and development efforts to this specific area. Their goal is to improve cancer treatment outcomes for patients with RAS mutations by providing effective targeted therapies.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased interest in targeted therapies boosts investment and partnership opportunities.
  • Trend towards personalized medicine aligns with their focus on RAS-driven cancers.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and delay product timelines.
  • Public stock offering may dilute shareholder value, causing investor dissatisfaction.
  • Focus on RAS-addicted cancers limits market scope amid potential competing therapies.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?